{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-126797","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.532210+00:00","generated_at":"2026-06-21T04:48:12.197325+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Voyager Therapeutics appoints Grace E. Colón, Ph.D. to board of directors, effective Jan 1, 2023","bullets":["Grace E. Colón appointed as Class I director; term runs until 2025 annual meeting.","Annual cash retainer of $40,000 for board service; $6,000 for Compensation Committee membership.","Initial option grant of 44,000 shares vesting quarterly over four years; annual option of 22,000 shares thereafter.","Dr. Colón also serves as Executive Chair of ProterixBio and director of CareDx; no family relationships with officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-126797","json":"https://secwatch.observer/filing/0001104659-22-126797.json","markdown":"https://secwatch.observer/filing/0001104659-22-126797.md","text":"https://secwatch.observer/filing/0001104659-22-126797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922126797/0001104659-22-126797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922126797/tm2232536d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:48:12.197325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a49423386","claim":"Grace E. Colón was appointed as director at Voyager Therapeutics, Inc..","evidence_excerpt":"appointed Grace E. Colón, Ph.D. as a director of the Company and as a member of the Compensation Committee of the Board, effective January 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922126797/0001104659-22-126797-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}